Hello hanscott. On expanding the antigen mix, I also wondered why as it just made sense to me that different cancers would have different "optimal" antigen candidates. I think they went with the original because they just wanted to run with what they had at the time. A bird in the hand is better than 2 in the bush.
From everything I got from Phantom, the adjuvant should do like 100 times better than the active, for obvious reasons.
I think the active AML data that was supposed to be Q1 is now Q2, so by June? P.S. Phantom just informed me "No adjuvant data this year. The data that was upcoming was from the active group. Adjuvant data is likely a ways off. Especially now that they delayed the trial"
On institutional holdings, I would love to see that myself. Is NEA still in? Others?
On clinical enrollment, I have asked MANY TIMES, if the technology was so great, like most of believe it is, then WHY are not Doctors referring their patients to Marker in droves? WHY is it taking so long to get to full enrollment?
Good Luck my Friend. All my Best Wishes to you and your family.
News 
Market Data 
Discover 
AI
